12/06/2026
GLP-1 therapeutics are rewriting biopharma—and analytical science is stepping up. 🔬💊
In Concentrating on Chromatography, Kelly Broster McMahon (Thermo Fisher Scientific) joins David Oliva to unpack how LC‑MS and high‑resolution MS deliver safe, effective GLP‑1 drugs like semaglutide. 🧪
• Why GLP‑1 peptides challenge labs: complex structures, modifications, degradation risk 🧬
• LC‑MS + UHPLC separate look‑alikes, confirm structure, and spot ppb impurities 🔎
• Find sequence variants, oxidation/deamidation, aggregates → protect patients 🛡️
• Scalable workflows from discovery → QC → manufacturing; strong data integrity and compliance ✅🏭
• What’s next: faster separations, multiplexing, AI, automation, PAT, real‑time insights 🚀
• Key takeaway: success isn’t more data—it’s measuring the right attributes earlier, with confidence. 💡
Watch the episode to see how integrated chromatography, HRAM MS, and informatics power biosimilars, equivalence testing, and the next decade of biopharma. 📈
Learn how chromatography, HRAM mass spectrometry, and AI-driven workflows support GLP-1 therapeutics, peptide characterization, and drug development.